Results 31 to 40 of about 10,559 (201)

CXCR7 in tumorigenesis and progression

open access: yesChinese Journal of Cancer, 2010
Chemokines, a family of small cytokines, were initially characterized as proinflammatory chemoattractant cytokines that regulated cell trafficking and adhesion. Today, attention focuses on chemokines because evidence shows that they play a critical role in tumor initiation, promotion, and progression.
Kai-Lin, Hou   +3 more
openaire   +2 more sources

CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes [PDF]

open access: yesCurrent Drug Targets, 2016
Many studies have suggested that CXCR3, CXCR5, CXCR6 and CXCR7 chemokine receptors are determinant in type 1 diabetes (T1D), expecially in autoimmunity and β-cell destruction. In particular circulating CXCL10 level (the ligand of CXCR3) is high in T1D patients, and this suggests that CXCL10 may be a candidate for a predictive marker of T1D.
Fallahi, P.   +5 more
openaire   +3 more sources

Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer

open access: yesJournal of Experimental & Clinical Cancer Research, 2023
Background The Hippo pathway is crucial in organ size control and tumorigenesis. Dysregulation of the Hippo/YAP axis is commonly observed in gastric cancer, while effective therapeutic targets for the Hippo/YAP axis are lacking.
Tianshi Wang   +16 more
doaj   +1 more source

Questions about Chemokine and Chemokine Receptor Antagonism in Renal Inflammation [PDF]

open access: yes, 2010
Chemokines remain attractive therapeutic targets for modulating inflammatory diseases in all areas of medicine including acute and chronic kidney disease.
Anders, Hans-Joachim   +2 more
core   +1 more source

Pathogenic role of CXCR7 in rheumatoid arthritis [PDF]

open access: yesArthritis & Rheumatism, 2010
AbstractObjectiveThe interaction between CXCL12 and its receptor, CXCR4, in the synovium of patients with rheumatoid arthritis (RA) is important for local inflammatory cell recruitment, angiogenesis, and cytokine production. CXCR7 was recently identified as an alternative receptor for CXCL12.
Kaori, Watanabe   +9 more
openaire   +2 more sources

Atypical Roles of the Chemokine Receptor ACKR3/CXCR7 in Platelet Pathophysiology

open access: yesCells, 2022
The manifold actions of the pro-inflammatory and regenerative chemokine CXCL12/SDF-1α are executed through the canonical GProteinCoupledReceptor CXCR4, and the non-canonical ACKR3/CXCR7.
Madhumita Chatterjee
doaj   +1 more source

Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth

open access: yesThe Journal of Clinical Investigation, 2023
CXCR7 is an atypical chemokine receptor that recruits β-arrestin (ARRB2) and internalizes into clathrin-coated intracellular vesicles where the complex acts as a scaffold for cytoplasmic kinase assembly and signal transduction. Here, we report that CXCR7
Galina Gritsina   +14 more
doaj   +1 more source

Lipopolysaccharide Promotes Choroidal Neovascularization by Up-Regulation of CXCR4 and CXCR7 Expression in Choroid Endothelial Cell. [PDF]

open access: yesPLoS ONE, 2015
Stromal cell-derived factor-1 (SDF-1) has been confirmed to participate in the formation of choroidal neovascularization (CNV) via its two receptors: CXC chemokine receptors 4 (CXCR4) and CXCR7. Previous studies have indicated that the activation of Toll-
Yi-fan Feng   +3 more
doaj   +1 more source

CXCL12, CXCR4 and CXCR7 expression in brain metastases [PDF]

open access: yesCancer Biology & Therapy, 2009
Brain metastases occur in about 25% of patients who die of cancer. The most common sources of brain metastases in adults are lung, breast, kidney, colorectal cancer and melanoma. The chemokine/receptor system CXCL12/CXCR4 plays a key role in multiple biological functions; among these, homing of neoplastic cells from the primary site to the target and ...
Salmaggi, Andrea   +9 more
openaire   +4 more sources

Targeting CXCR7/ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system [PDF]

open access: yes, 2014
Current treatment modalities for the neurodegenerative disease multiple sclerosis (MS) use disease-modifying immunosuppressive compounds but do not promote repair. Although several potential targets that may induce myelin production have been identified,
Arnett   +35 more
core   +2 more sources

Home - About - Disclaimer - Privacy